Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


New strategy may protect brain against stroke, Parkinson’s and Alzheimer’s


Researchers at the National Institutes of Health have developed several drug candidates that show promise in animal studies in protecting the brain against sudden damage from stroke, with the potential for fighting chronic neurodegenerative conditions like Parkinson’s and Alzheimer’s disease. The drugs, called p53 inhibitors, attack a key protein involved in nerve cell death and represent a new strategy for preserving brain function following sudden injury or chronic disease, according to the researchers.

Their findings will appear in the Nov. 7 print issue of the Journal of Medicinal Chemistry, a peer-reviewed publication of the American Chemical Society, the world’s largest scientific society.

"This is a completely new therapeutic strategy for Alzheimer’s and other neurodegenerative diseases, which warrants further assessment to allow it to move to clinical trials," says Nigel H. Greig, Ph.D., a researcher with the National Institute on Aging’s Intramural Research Program in Baltimore, Md., and chief investigator for the study. "If it works, it could provide a new treatment approach for a wide range of neurological diseases."

The research is limited to cell and animal studies for now, but if all goes well, human clinical trials could begin in two to three years, Greig says. The new drugs could provide relief for millions of Americans who suffer from mental and physical decline due to neurological damage and offer hope to those who are at increased risk due to advancing age.

Drugs currently used to treat neurological disease and injuries provide temporary relief of symptoms but do not stop or slow the underlying neurodegenerative process. The new experimental drugs, by contrast, target the common, underlying cause of this destructive process: the death of brain cells.

"By turning off cell death, you rescue brain cells from lethal insult," Greig says. He compares other drugs to "bandages" that help alleviate brain damage after it occurs, whereas p53 inhibitors act as "seat belts" that help prevent damage from occurring in the first place.

The main target of these drugs, p53, is a common protein found in cells that triggers the biochemical cascade of events leading to cell death. As cells die, new, healthy ones normally replace them. But in the diseased or injured brain, cell death can cause devastating damage, as brain cells cannot regenerate. The researchers theorized that by inactivating the protein temporarily, further brain damage might be prevented.

The researchers identified one compound, called pifithrin-alpha (PFT), which was shown in previous studies to inhibit p53. They then designed, synthesized and tested analogues of this compound to see whether they would work against cultured brain cells and animal models of neurodegenerative disease.

In laboratory tests, brain cells exposed to a series of toxic chemicals survived longer when given the inhibitor compound. In subsequent tests using a rodent model of stroke, the severity of stroke damage was significantly decreased in animals that received the inhibitor compounds compared to those that did not receive it, the researchers found.

Evidence for the drugs’ potential effectiveness against chronic neurodegenerative diseases is growing. In a related study, the researchers found that the drugs appear to prevent nerve damage in a mouse model of Parkinson’s disease.

In another study, the researchers showed that the compounds protect brain cells against beta amyloid, a toxic protein associated with Alzheimer’s disease. They are now planning to test the experimental drugs in animal models of the disease.

The new drugs will probably first be used to treat stroke, brain injury (from sports and motor vehicle accidents) or other conditions characterized by sudden brain trauma, the researchers say. If the compounds prove safe, they could later be extended to long-term diseases like Alzheimer’s, Parkinson’s, and Lou Gehrig’s (amyotrophic lateral sclerosis, or ALS).

The researchers caution that they need to first make sure that the inhibitors don’t cause side effects in other cells of the body. Other studies show that mice that have no p53 have an increased incidence of cancer, while those that have high levels of p53 experience premature aging.

"You have to have just the right balance," Greig says. Ideally, the compounds will work only temporarily and will then be broken down by the body.

Greig and his associates are currently testing various drug analogues to see which ones work the best. Once developed, the drugs can either be used as an oral pill or intravenously, depending on how quickly they need to be administered.

The National Institute on Aging provided funding for this study.

Dr. Greig’s associates in this study were Xiaoxiang Zhu, Ph.D., Qian-sheng Yu, Ph.D., Roy G. Cutler, M.S., Carsten W. Culmsee, Ph.D., Harold W. Holloway, B.S., Mark P. Mattson, Ph.D., all of the NIA’s Intramural Research Program; and Debomoy K. Lahiri, Ph.D., of Indiana University School of Medicine in Indianapolis, Ind.

The online version of the research paper cited above was initially published Oct. 3 on the journal’s Web site. Journalists can arrange access to this site by sending an e-mail to or calling the contact person for this release.

Nigel H. Greig, Ph.D., is chief of the Drug Design & Development Section in the Laboratory of Neurosciences at the National Institute on Aging’s Intramural Research Program in Baltimore, Md.

Beverly Hassell | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Inflammation Triggers Unsustainable Immune Response to Chronic Viral Infection
24.10.2016 | Universität Basel

nachricht Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Etching Microstructures with Lasers

Ultrafast lasers have introduced new possibilities in engraving ultrafine structures, and scientists are now also investigating how to use them to etch microstructures into thin glass. There are possible applications in analytics (lab on a chip) and especially in electronics and the consumer sector, where great interest has been shown.

This new method was born of a surprising phenomenon: irradiating glass in a particular way with an ultrafast laser has the effect of making the glass up to a...

Im Focus: Light-driven atomic rotations excite magnetic waves

Terahertz excitation of selected crystal vibrations leads to an effective magnetic field that drives coherent spin motion

Controlling functional properties by light is one of the grand goals in modern condensed matter physics and materials science. A new study now demonstrates how...

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Ice shelf vibrations cause unusual waves in Antarctic atmosphere

25.10.2016 | Earth Sciences

Fluorescent holography: Upending the world of biological imaging

25.10.2016 | Power and Electrical Engineering

Etching Microstructures with Lasers

25.10.2016 | Process Engineering

More VideoLinks >>>